Published in Antivir Ther on January 01, 2007
Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS (2008) 13.25
Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet (2010) 5.41
Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS (2008) 3.71
Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Med (2008) 3.56
Long term outcomes of antiretroviral therapy in a large HIV/AIDS care clinic in urban South Africa: a prospective cohort study. J Int AIDS Soc (2009) 2.44
Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysis. PLoS Med (2010) 2.10
Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Côte d'Ivoire. PLoS One (2010) 2.05
Universal antiretroviral therapy for HIV infection: should US treatment guidelines be applied to resource-limited settings? Clin Infect Dis (2013) 1.92
Antiretroviral treatment changes in adults from Côte d'Ivoire: the roles of tuberculosis and pregnancy. AIDS (2010) 1.68
Projecting the clinical benefits and risks of using efavirenz-containing antiretroviral therapy regimens in women of childbearing age. AIDS (2012) 1.57
Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial. J Acquir Immune Defic Syndr (2009) 1.45
Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America. PLoS One (2010) 1.37
Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania. AIDS Res Hum Retroviruses (2009) 1.32
Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy. Clin Infect Dis (2009) 1.30
Early adherence to antiretroviral medication as a predictor of long-term HIV virological suppression: five-year follow up of an observational cohort. PLoS One (2010) 1.28
Incidence of treatment-limiting toxicity with stavudine-based antiretroviral therapy in Cambodia: a retrospective cohort study. PLoS One (2012) 1.23
HIV treatment and care in resource-constrained environments: challenges for the next decade. J Int AIDS Soc (2012) 1.21
Drug susceptibility and resistance mutations after first-line failure in resource limited settings. Clin Infect Dis (2014) 1.19
Improved antiretroviral treatment outcome in a rural African setting is associated with cART initiation at higher CD4 cell counts and better general health condition. BMC Infect Dis (2011) 1.14
Short-term risk of anaemia following initiation of combination antiretroviral treatment in HIV-infected patients in countries in sub-Saharan Africa, Asia-Pacific, and central and South America. J Int AIDS Soc (2012) 1.10
Scaling up antiretroviral therapy in developing countries: what are the benefits and challenges? Sex Transm Infect (2007) 1.08
A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects. BMC Infect Dis (2011) 1.07
Expanding antiretroviral options in resource-limited settings--a cost-effectiveness analysis. J Acquir Immune Defic Syndr (2009) 0.99
Quality of life and the impact of drug toxicities in a South African community-based antiretroviral programme. J Int AIDS Soc (2009) 0.98
Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa. J Int AIDS Soc (2013) 0.94
Rates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovir. PLoS One (2013) 0.93
Pharmacovigilance for antiretroviral drugs in Africa: lessons from a study in Abidjan, Cote d'Ivoire. Pharmacoepidemiol Drug Saf (2011) 0.92
HIV/AIDS and lipodystrophy: implications for clinical management in resource-limited settings. J Int AIDS Soc (2015) 0.91
Disease patterns and causes of death of hospitalized HIV-positive adults in West Africa: a multicountry survey in the antiretroviral treatment era. J Int AIDS Soc (2014) 0.91
Implementation of a validated peripheral neuropathy screening tool in patients receiving antiretroviral therapy in Mombasa, Kenya. Am J Trop Med Hyg (2010) 0.91
Underreporting of side effects of standard first-line ART in the routine setting in Blantyre, Malawi. Malawi Med J (2011) 0.87
Patent Pooling for Promoting Access to Antiretroviral Drugs (ARVs) - A Strategic Option for India. Open AIDS J (2010) 0.87
Initiating antiretrovirals during tuberculosis treatment: a drug safety review. Expert Opin Drug Saf (2011) 0.85
Incidence and predictors of first line antiretroviral regimen modification in western Kenya. PLoS One (2014) 0.84
Adult combination antiretroviral therapy in sub-Saharan Africa: lessons from Botswana and future challenges. HIV Ther (2009) 0.83
Lack of association between stavudine exposure and lipoatrophy, dysglycaemia, hyperlactataemia and hypertriglyceridaemia: a prospective cross sectional study. AIDS Res Ther (2010) 0.83
Improved survival in HIV treatment programmes in Asia. Antivir Ther (2016) 0.83
Hyperlactatemia in a group of HIV patients living in Yaounde-Cameroon. AIDS Res Ther (2014) 0.82
Outcomes in a Cohort of Patients Started on Antiretroviral Treatment and Followed up for a Decade in an Urban Clinic in Uganda. PLoS One (2015) 0.81
Evaluation of antiretroviral therapy (ART) provision in an early cohort of patients initiating ART in Ghana. Pan Afr Med J (2013) 0.80
A risk-factor guided approach to reducing lactic acidosis and hyperlactatemia in patients on antiretroviral therapy. PLoS One (2011) 0.80
Short communication: Severe symptomatic hyperlactatemia among HIV type 1-infected adults on antiretroviral therapy in Côte d'Ivoire. AIDS Res Hum Retroviruses (2010) 0.80
Frequency and characteristics of HIV-associated sensory neuropathy among HIV patients in Bangkok, Thailand. J Acquir Immune Defic Syndr (2008) 0.79
Determinants of Weight Evolution Among HIV-Positive Patients Initiating Antiretroviral Treatment in Low-Resource Settings. J Acquir Immune Defic Syndr (2015) 0.78
Incidence and determinants of nevirapine and efavirenz-related skin rashes in West Africans: nevirapine's epitaph? PLoS One (2014) 0.78
Sex differences in the incidence of peripheral neuropathy among Kenyans initiating antiretroviral therapy. Clin Infect Dis (2011) 0.78
Reduced referral and case fatality rates for severe symptomatic hyperlactataemia in a South African public sector antiretroviral programme: a retrospective observational study. AIDS Res Ther (2010) 0.76
Association Between the Occurrence of Adverse Drug Events and Modification of First-Line Highly Active Antiretroviral Therapy in Ghanaian HIV Patients. Drug Saf (2016) 0.76
Systematic review of statistically-derived models of immunological response in HIV-infected adults on antiretroviral therapy in Sub-Saharan Africa. PLoS One (2017) 0.75
Targeted Spontaneous Reporting: Assessing Opportunities to Conduct Routine Pharmacovigilance for Antiretroviral Treatment on an International Scale. Drug Saf (2016) 0.75
Urine methylmalonic acid levels in HIV-infected adults with peripheral neuropathy. Caspian J Intern Med (2013) 0.75
Performance of Celera RUO integrase resistance assay across multiple HIV-1 subtypes. J Virol Methods (2016) 0.75
Five-year trends in treatment changes in an adult cohort of HIV/AIDS patients in Ghana: a retrospective cohort study. BMC Infect Dis (2017) 0.75
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet (2006) 31.79
CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ (2010) 28.70
Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet (2008) 20.62
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet (2007) 20.57
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med (2015) 15.06
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ (2007) 14.52
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol (2008) 14.36
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (2009) 14.01
Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS (2008) 13.25
Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS (2009) 11.62
Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS (2005) 11.25
Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS (2004) 11.18
Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (2008) 11.08
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med (2007) 10.43
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet (2004) 9.88
Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis (2006) 9.25
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med (2007) 8.77
Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet (2004) 8.77
Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ (2008) 8.70
Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One (2009) 8.58
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med (2007) 8.46
Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy. Lancet (2005) 7.89
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med (2007) 7.87
Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis (2011) 7.23
CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol (2010) 7.04
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet (2009) 6.92
Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ (2011) 6.89
Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS (2005) 6.83
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis (2008) 6.73
Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet (2005) 6.60
Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet (2002) 6.54
Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa. S Afr Med J (2006) 6.29
Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med (2007) 6.26
Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet (2010) 6.02
Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis (2008) 5.94
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology (2007) 5.77
Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. Clin Infect Dis (2006) 5.68
Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS (2003) 5.52
Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS (2010) 5.46
A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med (2006) 5.43
Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS (2007) 5.41
Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet (2010) 5.41
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull World Health Organ (2007) 5.38
Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health (2008) 5.32
Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis (2007) 5.32
Implementing antiretroviral therapy in rural communities: the Lusikisiki model of decentralized HIV/AIDS care. J Infect Dis (2007) 5.27
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology (2007) 5.12
Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med (2011) 5.06
HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet (2006) 5.00
Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr (2006) 4.81
Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol (2003) 4.77
Home visits to prevent nursing home admission and functional decline in elderly people: systematic review and meta-regression analysis. JAMA (2002) 4.75
How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol (2002) 4.68
Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. AIDS (2010) 4.68
Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis (2010) 4.56
Antiretroviral therapy and early mortality in South Africa. Bull World Health Organ (2008) 4.54
Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ (2009) 4.38
Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration. J Womens Health (Larchmt) (2008) 4.38
When to start antiretroviral therapy in resource-limited settings. Ann Intern Med (2009) 4.31
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS (2007) 4.31
Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med (2011) 4.29
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Prev Med (2007) 4.29
Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet (2010) 4.23
Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS (2009) 4.07
What is newsworthy? Longitudinal study of the reporting of medical research in two British newspapers. BMJ (2002) 4.05
Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet (2004) 3.96
Regional differences in prevalence of HIV-1 discordance in Africa and enrollment of HIV-1 discordant couples into an HIV-1 prevention trial. PLoS One (2008) 3.94
Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test. J Clin Epidemiol (2004) 3.93
High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis (2008) 3.92
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol (2009) 3.91
Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS (2009) 3.91
Electronic medical record systems, data quality and loss to follow-up: survey of antiretroviral therapy programmes in resource-limited settings. Bull World Health Organ (2008) 3.85
Direction and impact of language bias in meta-analyses of controlled trials: empirical study. Int J Epidemiol (2002) 3.79
Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis (2009) 3.77
Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS One (2009) 3.66
Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther (2007) 3.60
Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med (2005) 3.60
Quality of reporting of randomized trials as a measure of methodologic quality. JAMA (2002) 3.60
CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int J Surg (2011) 3.57
Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Med (2008) 3.56
Effectiveness of the first district-wide programme for the prevention of mother-to-child transmission of HIV in South Africa. Bull World Health Organ (2005) 3.51
Linkage to HIV care and antiretroviral therapy in Cape Town, South Africa. PLoS One (2010) 3.48
Loss to programme between HIV diagnosis and initiation of antiretroviral therapy in sub-Saharan Africa: systematic review and meta-analysis. Trop Med Int Health (2012) 3.43
Mortality of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa: comparison with HIV-unrelated mortality. PLoS Med (2009) 3.42
CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med (2003) 3.41